NVO

There is no current bill filed. Issues related to anti-obesity medications, drug pricing, and pharmaceutical supply chain.

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding International and corporate tax issues Tariffs and trade policy

Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. Issues related to tariffs. Issues related to importation of counterfeit drugs.

Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines.

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. Support for obesity drug coverage and access. Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21. General issues related to patent protections.

Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act.

IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages, drug supply chain Treat and Reduce Obesity Act, obesity treatment Federal budget issues

Issues related to obesity; Issues related to medication affordability and access

Issues related to general compounding. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973). Issues related to general compounding.